Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 405 Brain Neoplasms 163 Glioma 159 Gliosarcoma 131 Astrocytoma 115 Central Nervous System Neoplasms 110 Melanoma 75 Oligodendroglioma 74 Neuroblastoma 44 Neoplasms 33 Medulloblastoma 33 Neoplasm Metastasis 29 Recurrence 28 Ependymoma 26 Sarcoma 23 Sarcoma, Ewing 22 Rhabdomyosarcoma 18 Small Cell Lung Carcinoma 16 Lymphoma 16 Carcinoma, Non-Small-Cell Lung 16 Diffuse Intrinsic Pontine Glioma 15 Lung Neoplasms 14 Breast Neoplasms 14 Ovarian Neoplasms 13 Neuroendocrine Tumors 13 Choroid Plexus Neoplasms 13 Optic Nerve Glioma 11 Neuroectodermal Tumors, Primitive 11 Spinal Cord Neoplasms 10 Rhabdoid Tumor 10

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Temozolomide × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡